Clinical trial
Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected…
NCT00279721 · Alberta Health services, Other · Completed
Key facts
| NCT number | NCT00279721 |
|---|---|
| Title | Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer. |
| Official title | Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer. |
| Lead sponsor | Alberta Health services, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thyroid Neoplasms |
| Intervention type | Procedure |
| Interventions | IMRT |
| Enrollment | 40 |
| Start date | Jan 1, 2006 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Jan 20, 2006 |
| Last update posted | Jan 19, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: